enVVeno Medical (NASDAQ:NVNO – Get Free Report) and Cerus (NASDAQ:CERS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Risk & Volatility
enVVeno Medical has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Cerus has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Profitability
This table compares enVVeno Medical and Cerus’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enVVeno Medical | N/A | -48.72% | -45.96% |
Cerus | -11.19% | -37.90% | -10.35% |
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enVVeno Medical | 0 | 0 | 0 | 0 | 0.00 |
Cerus | 0 | 1 | 3 | 0 | 2.75 |
Cerus has a consensus target price of $3.63, indicating a potential upside of 105.97%. Given Cerus’ stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than enVVeno Medical.
Valuation & Earnings
This table compares enVVeno Medical and Cerus”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
enVVeno Medical | N/A | N/A | -$23.52 million | ($1.29) | -2.49 |
Cerus | $156.37 million | 2.09 | -$37.49 million | ($0.11) | -16.00 |
enVVeno Medical has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 16.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 3.4% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Cerus beats enVVeno Medical on 8 of the 13 factors compared between the two stocks.
About enVVeno Medical
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
About Cerus
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.